Exhibit 99.1

FOR IMMEDIATE RELEASE

Contact:  Cheryl Johnson
          Vice President, Investor Relations
          NOVOSTE CORPORATION
          (770) 717-6052

                 NOVOSTE RAISES $46 MILLION IN PRIVATE PLACEMENT

NORCROSS, GA., April 4, 2000 - Novoste Corporation (Nasdaq: NOVT) announced
today that it has completed a private placement of 1,313,500 shares of common
stock at $35.00 per share, raising gross proceeds of $46 million. The Company
expects to complete the placement of an additional 150,000 shares by the end of
the week, bringing the total gross proceeds to $51.2 million. U.S. Bancorp Piper
Jaffray served as placement agent to institutional investors participating in
the financing.

The Company intends to use the proceeds from the financing to prepare for U.S.
market introduction of the Beta-Cath(TM) System pending FDA approval, to expand
its international sales and marketing efforts, to continue product development
and clinical trials, and for working capital and other general corporate
purposes.

An additional 186,500 shares from selling shareholders were included in the
transaction, primarily to address alternative minimum tax liabilities associated
with the exercise of stock options during 1999.

The common stock sold to the investors has not been registered under the
Securities Act of 1933. Accordingly, these shares may not be offered or sold in
the United States, except pursuant to the effectiveness of a registration
statement or an applicable exemption from the registration requirements of the
Securities Act. Novoste has agreed to file a registration statement covering
resales of these shares with the investors. This press release shall not
constitute an offer to sell or the solicitation of an offer to buy any
securities.

Novoste Corporation, based in Atlanta, Ga., is a leader in the emerging field of
vascular brachytherapy to reduce the incidence of restenosis. The Company
recently announced the results of its pivotal START Trial, which showed that
treatment with the Beta-Cath(TM) System significantly reduced the risk of repeat
blockage and additional treatment for patients suffering from blocked stents,
when compared to patients treated with placebo. The Beta-Cath(TM) System is
commercially available in the European Union, Israel, Turkey, Australia, New
Zealand, China, Singapore and India. For more information about Novoste, please
call (770) 717-0904 or visit the company's web site at www.novoste.com.

Except for the historical information contained herein, the matters set forth in
this press release, such as statements as to the expected use of net proceeds,
are forward-looking statements within the meaning of the "safe harbor"
provisions of the Private Securities Litigation Reform Act of 1995. These
forward-looking statements are subject to risks and uncertainties including the
continued demonstration of safety and efficacy of the Beta-Cath(TM) System,
receipt and timing of regulatory approvals, market acceptance and availability
of the Beta-Cath(TM) System, and other risks detailed in documents filed by
Novoste with the SEC, including Forms 10-K and 10-Q.

                                     # # #